We are live on ! Find out more
BCLSI

Bain Capital Life Sciences Investors Portfolio holdings

AUM $1.11B
1-Year Est. Return 171.34%
This Fund
S&P 500
This Quarter Est. Return
+32.52%
1 Year Est. Return
+171.34%
3 Year Est. Return
+643.23%
5 Year Est. Return
+451.99%
10 Year Est. Return
–
AUM
$971M
AUM Growth
+$171M
Cap. Flow
+$9.16M
Cap. Flow %
0.94%
Top 10 Hldgs %
68.82%
Holding
35
New
1
Increased
4
Reduced
3
Closed
3

Top Buys

Rank Stock Value
1
NAMS icon
NewAmsterdam Pharma
NAMS
+$28.8M
2
CABA icon
Cabaletta Bio
CABA
+$21.7M
3
PHVS icon
Pharvaris
PHVS
+$16.3M
4
XFOR icon
X4 Pharmaceuticals
XFOR
+$6.44M
5
ANNX icon
Annexon
ANNX
+$3.56M

Top Sells

Rank Stock Value
1
IRON icon
Disc Medicine
IRON
+$23.4M
2
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$19.8M
3
DVAX
Dynavax Technologies
DVAX
+$17.1M
4
TVRD
Tvardi Therapeutics
TVRD
+$4.86M
5
SYRE icon
Spyre Therapeutics
SYRE
+$1.55M

Sector Composition

Rank Sector Weight
1 Healthcare 98.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SYRS
26
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$6.69M 0.69%
2,124,694
– –
TNGX icon
27
Tango Therapeutics
TNGX
$4.31B
$6.38M 0.66%
1,921,790
– –
CCCC icon
28
C4 Therapeutics
CCCC
$480M
$4.52M 0.47%
1,642,210
– –
THRD
29
DELISTED
Third Harmonic Bio
THRD
$3.08M 0.32%
640,631
– –
TVRD
30
Tvardi Therapeutics
TVRD
$22.1M
$2.65M 0.27%
25,969
-35,266
-58% -$4.86M
IVVD icon
31
Invivyd
IVVD
$216M
$2.03M 0.21%
1,937,207
– –
NAMSW icon
32
NewAmsterdam Pharma Warrant
NAMSW
$78.2M
$209K 0.02%
100,000
– –
SYRE icon
33
Spyre Therapeutics
SYRE
$9.18B
– –
-213,908
Closed -$1.55M
APTX
34
DELISTED
Aptinyx Inc. Common Stock
APTX
– –
-8,891,758
Closed -$1.11M
CTIC
35
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
– –
-4,702,996
Closed -$19.8M
1
2

Similar funds

JTWM
Jackson Thornton Wealth Management Montgomery, Alabama $1.11B AUM 22.53% 1-Year Est. Return
HH
Hilltop Holdings Dallas, Texas $1.11B AUM 24.7% 1-Year Est. Return
RIM
Rockbridge Investment Management Syracuse, New York $1.11B AUM 13.62% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
AIM
Advyzon Investment Management Lisle, Illinois $1.12B AUM 22.08% 1-Year Est. Return
MTCM
Mint Tower Capital Management Amsterdam, Netherlands $1.12B AUM 18.84% 1-Year Est. Return
CNC
Canandaigua National Corp Canandaigua, New York $1.12B AUM

Bain Capital Life Sciences Investors's Q2 2023 Portfolio in Review

As of Q2 2023, Bain Capital Life Sciences Investors held 35 positions worth $971M, up 21% from $800M the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Bain Capital Life Sciences Investors's Q2 2023 filing shows 1 new, 4 increased, 3 reduced and 3 closed positions. Its largest new stake was Cabaletta Bio: 2,000,000 shares worth $25.8M. The largest sale was Disc Medicine, an estimated $23.4M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier.

  • Bain Capital Life Sciences Investors's largest Q2 2023 buy was Cabaletta Bio: 2,000,000 shares worth $25.8M.
  • Bain Capital Life Sciences Investors added most to NewAmsterdam Pharma in Q2 2023, an estimated $28.8M increase.
  • Bain Capital Life Sciences Investors's biggest Q2 2023 reduction was Disc Medicine, cutting an estimated $23.4M.
  • Bain Capital Life Sciences Investors fully exited CTI BioPharma Corp. (DE) Common Stock in Q2 2023, selling an estimated $19.8M.
  • Bain Capital Life Sciences Investors's ten largest holdings make up 69% of its $971M portfolio in Q2 2023.
  • Bain Capital Life Sciences Investors opened 1 new position and closed 3 in Q2 2023.
  • Bain Capital Life Sciences Investors's portfolio value rose 21% quarter-over-quarter to $971M.

Based on Bain Capital Life Sciences Investors's 13F filing for Q2 2023, filed 14 Aug 2023.